<Anchor>
Controversy continues over the AstraZeneca vaccine.
The claim is that the vaccine is less effective for older people, but AstraZeneca countered that it was not true.
The European Union, which is currently evaluating whether to use the AstraZeneca vaccine, said it would carefully review the age range.
This news is reporter Jung Hye-kyung.
<Reporter>
It was reported by several German media that recently sparked the controversy about the efficacy of the AstraZeneca vaccine.
According to an official from the German government, the AstraZeneca vaccine is less than 8% effective in the elderly over the age of 65, and that is why the European Medicines Agency may not approve vaccination for the elderly.
In response, the German government said the media report was false, but it was true that AstraZeneca's clinical data for seniors were insufficient.
As the controversy grew, AstraZeneca strongly refuted that it was not true.
AstraZeneca explained that 100% of the antibodies were formed in elderly subjects after the second vaccination in clinical trials.
With the decision to approve the AstraZeneca vaccine this week, the European Medicines Agency has been cautious.
European Medicines Commissioner Emma Cook attended the Health Commission, suggesting that AstraZeneca could limit the age group to young people.
[Emer Cook/Director of the European Medicines Agency: Clinical trials for the elderly were conducted for very few recruits.] The
AstraZeneca vaccine is currently approved for emergency use in Brazil, Argentina, and India, led by the UK.
(Video coverage: Youngchun Oh, video editing: Jongmi Kim)
▶ Announcement of vaccination plan on the 28th…
The first vaccination potential of'Astra'